FDA litargirio warning
This article was originally published in The Rose Sheet
Executive SummaryConsumers should immediately stop all use of litargirio powder, which is commonly found in deodorant, foot fungicide and burn and wound treatment products, agency announces. FDA is working with the Consumer Product Safety Commission to alert public to risks of lead poisoning after ingestion or contact with skin. Powder is a traditional remedy popular in the Dominican Republic that does not have any proven health benefits and is particularly harmful to children, agency points out. Rhode Island Department of Health alerted FDA to product's dangers after several children using litargirio as deodorant were treated for lead poisoning...
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.